A post-restructuring medtech franchise aiming to convert robotics-led share gains and consumables-heavy revenue into a margin and valuation re-rating—while navigating tariffs, reimbursement, China VBP, and activist pressure.
Overview
Smith & Nephew (SN.L) is a global medical technology company headquartered in the UK, operating in 100+ countries with a mission focused on repairing, regenerating, and replacing soft and hard tissue (“Life Unlimited”). It serves hospitals, academic centers, ASCs, and home-health settings with engineered implants, surgical robotics, biologic healing solutions, and advanced dressings. In 2025 it generated $6.164B revenue and had a market cap of ~£11.8B. The business is organized into three global divisions: (1) Orthopaedics ($2.64B; ~43% of revenue), spanning hips/knees, trauma/extremities, and the CORI robotic ecosystem that creates high switching costs and recurring consumables pull-through; (2) Sports Medicine & ENT (~$1.9B; ~32%), built around arthroscopy, imaging towers, and high-margin consumables (anchors, sutures, REGENETEN), with ENT more procurement-price sensitive; (3) Advanced Wound Management (~$1.6B; ~25%), a largely consumables model (ALLEVYN, PICO NPWT, SANTYL) benefiting from aging and diabetes-driven chronic wound prevalence. The U.S. is the profit anchor (53.6% of revenue in 2025). Emerging markets offer growth but China has been disrupted by VBP tenders (China revenue down from $275m in 2023 to $128m in 2025). Despite regional headwinds, the company delivered 5.3% underlying growth in 2025, reflecting improving operational stability and diversified end-market exposure.